|
Name |
Chaetomugilin F
|
Molecular Formula | C23H25ClO5 | |
IUPAC Name* |
(1R,10S,13R,14R)-8-chloro-10,13,14-trimethyl-5-[(E,3S)-3-methylpent-1-enyl]-4,11,15-trioxatetracyclo[8.7.0.02,7.012,17]heptadeca-2,5,7,12(17)-tetraene-9,16-dione
|
|
SMILES |
CC[C@H](C)/C=C/C1=CC2=C(C(=O)[C@@]3([C@H](C2=CO1)C4=C(O3)[C@@H]([C@H](OC4=O)C)C)C)Cl
|
|
InChI |
InChI=1S/C23H25ClO5/c1-6-11(2)7-8-14-9-15-16(10-27-14)18-17-20(12(3)13(4)28-22(17)26)29-23(18,5)21(25)19(15)24/h7-13,18H,6H2,1-5H3/b8-7+/t11-,12+,13+,18+,23-/m0/s1
|
|
InChIKey |
PQCNMEKFPHIIHE-QESWSWRDSA-N
|
|
Synonyms |
Chaetomugilin F; CHEMBL3621758; (1R,10S,13R,14R)-8-chloro-10,13,14-trimethyl-5-[(E,3S)-3-methylpent-1-enyl]-4,11,15-trioxatetracyclo[8.7.0.02,7.012,17]heptadeca-2,5,7,12(17)-tetraene-9,16-dione; 1098081-42-5
|
|
CAS | NA | |
PubChem CID | 25141203 | |
ChEMBL ID | CHEMBL3621758 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 416.9 | ALogp: | 4.2 |
HBD: | 0 | HBA: | 5 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 61.8 | Aromatic Rings: | 4 |
Heavy Atoms: | 29 | QED Weighted: | 0.596 |
Caco-2 Permeability: | -4.735 | MDCK Permeability: | 0.00001080 |
Pgp-inhibitor: | 0.998 | Pgp-substrate: | 0.006 |
Human Intestinal Absorption (HIA): | 0.011 | 20% Bioavailability (F20%): | 0.999 |
30% Bioavailability (F30%): | 0.96 |
Blood-Brain-Barrier Penetration (BBB): | 0.062 | Plasma Protein Binding (PPB): | 82.78% |
Volume Distribution (VD): | 2.722 | Fu: | 11.73% |
CYP1A2-inhibitor: | 0.956 | CYP1A2-substrate: | 0.367 |
CYP2C19-inhibitor: | 0.959 | CYP2C19-substrate: | 0.601 |
CYP2C9-inhibitor: | 0.926 | CYP2C9-substrate: | 0.027 |
CYP2D6-inhibitor: | 0.921 | CYP2D6-substrate: | 0.018 |
CYP3A4-inhibitor: | 0.957 | CYP3A4-substrate: | 0.677 |
Clearance (CL): | 3.855 | Half-life (T1/2): | 0.062 |
hERG Blockers: | 0.047 | Human Hepatotoxicity (H-HT): | 0.956 |
Drug-inuced Liver Injury (DILI): | 0.931 | AMES Toxicity: | 0.208 |
Rat Oral Acute Toxicity: | 0.874 | Maximum Recommended Daily Dose: | 0.908 |
Skin Sensitization: | 0.94 | Carcinogencity: | 0.849 |
Eye Corrosion: | 0.013 | Eye Irritation: | 0.044 |
Respiratory Toxicity: | 0.984 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002532 | 0.616 | D0C1SF | 0.231 | ||||
ENC002533 | 0.598 | D0K7LU | 0.208 | ||||
ENC002613 | 0.554 | D02GAC | 0.188 | ||||
ENC002501 | 0.500 | D0R6RC | 0.187 | ||||
ENC002525 | 0.495 | D0F4ZY | 0.182 | ||||
ENC001874 | 0.486 | D0S0LZ | 0.181 | ||||
ENC002612 | 0.480 | D0R9WP | 0.173 | ||||
ENC004258 | 0.473 | D08NQZ | 0.173 | ||||
ENC005844 | 0.471 | D0O6KE | 0.172 | ||||
ENC005878 | 0.471 | D0J2NK | 0.170 |